Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1272) 1272
Newspaper Article (35) 35
Newsletter (9) 9
Book Chapter (6) 6
Magazine Article (5) 5
Dissertation (2) 2
Transcript (2) 2
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1038) 1038
lopinavir (1019) 1019
science & technology (926) 926
life sciences & biomedicine (864) 864
hiv infections - drug therapy (701) 701
male (622) 622
female (596) 596
infectious diseases (538) 538
adult (502) 502
ritonavir - administration & dosage (492) 492
ritonavir (403) 403
ritonavir - therapeutic use (377) 377
biological and medical sciences (360) 360
medical sciences (358) 358
antiviral agents (357) 357
pyrimidinones - administration & dosage (357) 357
pharmacology & pharmacy (348) 348
hiv (336) 336
middle aged (333) 333
hiv protease inhibitors - administration & dosage (315) 315
anti-hiv agents - administration & dosage (289) 289
drug therapy, combination (287) 287
viral diseases (278) 278
human immunodeficiency virus--hiv (277) 277
pharmacology. drug treatments (269) 269
drug combinations (260) 260
pyrimidinones - therapeutic use (257) 257
hiv protease inhibitors - therapeutic use (247) 247
drug therapy (246) 246
lopinavir - administration & dosage (246) 246
human viral diseases (234) 234
immunology (229) 229
treatment outcome (229) 229
anti-hiv agents - therapeutic use (226) 226
virology (220) 220
ritonavir - adverse effects (218) 218
antiretroviral drugs (214) 214
microbiology (214) 214
hiv infections - virology (212) 212
viral load (210) 210
protease inhibitors (206) 206
viral diseases of the lymphoid tissue and the blood. aids (204) 204
antibiotics. antiinfectious agents. antiparasitic agents (200) 200
aids/hiv (185) 185
lopinavir - therapeutic use (184) 184
hiv protease inhibitors - adverse effects (172) 172
ritonavir - pharmacokinetics (171) 171
drug administration schedule (164) 164
pyrimidinones - adverse effects (164) 164
hiv-1 - drug effects (160) 160
covid-19 (159) 159
dosage and administration (150) 150
hiv infection (150) 150
drug interactions (144) 144
health aspects (144) 144
hiv protease inhibitors - pharmacokinetics (141) 141
pyrimidinones - pharmacokinetics (139) 139
coronaviruses (134) 134
cd4 lymphocyte count (133) 133
pharmacokinetics (131) 131
research (128) 128
antiretroviral therapy (127) 127
antiretroviral therapy, highly active (125) 125
clinical trials (125) 125
adolescent (123) 123
immunodeficiencies (121) 121
immunodeficiencies. immunoglobulinopathies (121) 121
immunopathology (121) 121
young adult (120) 120
tenofovir (119) 119
anti-hiv agents - adverse effects (117) 117
anti-hiv agents - pharmacokinetics (115) 115
virus diseases (113) 113
analysis (110) 110
highly active antiretroviral therapy (110) 110
animals (109) 109
lopinavir/ritonavir (108) 108
aged (107) 107
pharmacology (107) 107
hiv-1 (106) 106
patients (104) 104
human immunodeficiency virus (103) 103
lopinavir - pharmacokinetics (100) 100
pandemics (100) 100
ritonavir - pharmacology (100) 100
drugs (96) 96
child (94) 94
aids (93) 93
sars-cov-2 (90) 90
infant (89) 89
lopinavir - adverse effects (89) 89
atazanavir sulfate (87) 87
proteases (82) 82
care and treatment (81) 81
hiv protease inhibitors - pharmacology (81) 81
abridged index medicus (80) 80
hiv infections - blood (78) 78
rna, viral - blood (78) 78
anti-hiv agents (76) 76
reverse transcriptase inhibitors - administration & dosage (76) 76
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1276) 1276
Spanish (30) 30
German (22) 22
Japanese (5) 5
Portuguese (5) 5
French (4) 4
Russian (4) 4
Chinese (3) 3
Hungarian (1) 1
Italian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text COVID‐19 in kidney transplant recipients
by Gandolfini, Ilaria and Delsante, Marco and Fiaccadori, Enrico and Zaza, Gianluigi and Manenti, Lucio and Degli Antoni, Anna and Peruzzi, Licia and Riella, Leonardo V and Cravedi, Paolo and Maggiore, Umberto
American journal of transplantation, ISSN 1600-6135, 07/2020, Volume 20, Issue 7, pp. 1941 - 1943
colchicine | infectious disease | infection and infectious agents – viral | clinical research/practice | kidney transplantation/nephrology | immunosuppressive regimens | Transplantation | Life Sciences & Biomedicine | Surgery | Science & Technology | Pandemics | Humans | Middle Aged | Colchicine - administration & dosage | Male | Transplant Recipients | COVID-19 | SARS-CoV-2 | Darunavir - administration & dosage | Pneumonia, Viral - complications | Betacoronavirus | Coronavirus Infections - complications | Female | Mycophenolic Acid - administration & dosage | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Kidney Failure, Chronic - surgery | Cytokines - metabolism | Ritonavir - administration & dosage | Tacrolimus - blood | Pneumonia, Viral - therapy | Cobicistat - administration & dosage | Treatment Outcome | Kidney Transplantation | Hydroxychloroquine - administration & dosage | Coronavirus Infections - therapy | Kidney Failure, Chronic - complications | Lopinavir - administration & dosage | Aged | Drug Combinations | Kidney transplantation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience
by Testa, Sophie and Prandoni, Paolo and Paoletti, Oriana and Morandini, Rossella and Tala, Maurizio and Dellanoce, Claudia and Giorgi‐Pierfranceschi, Matteo and Betti, Monia and Battista Danzi, Gian and Pan, Angelo and Palareti, Gualtiero
Journal of thrombosis and haemostasis, ISSN 1538-7933, 06/2020, Volume 18, Issue 6, pp. 1320 - 1323
plasma level | anticoagulant | COVID‐19 | antiviral agents | DOAC | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Betacoronavirus - pathogenicity | Dabigatran - adverse effects | Dabigatran - administration & dosage | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Male | Antithrombins - administration & dosage | Pyridones - blood | Thiazoles - adverse effects | Factor Xa Inhibitors - administration & dosage | COVID-19 | Pyridines - adverse effects | SARS-CoV-2 | Drug Interactions | Factor Xa Inhibitors - blood | Pyrazoles - blood | Patient Safety | Aged, 80 and over | Pyridines - administration & dosage | Risk Assessment | Administration, Oral | Risk Factors | Antiviral Agents - administration & dosage | Coronavirus Infections - virology | Antiviral Agents - adverse effects | Factor Xa Inhibitors - adverse effects | Antithrombins - blood | Pneumonia, Viral - diagnosis | Italy | Darunavir - adverse effects | Hemorrhage - chemically induced | Thiazoles - blood | Pandemics | Thiazoles - administration & dosage | Pyridones - administration & dosage | Ritonavir - adverse effects | Female | Pyrazoles - adverse effects | Severity of Illness Index | Coronavirus Infections - diagnosis | Betacoronavirus - drug effects | Dabigatran - blood | Pyrazoles - administration & dosage | Pyridines - blood | Antithrombins - adverse effects | Aged | Drug Monitoring | Pneumonia, Viral - virology | Lopinavir - adverse effects | Pyridones - adverse effects | Anticoagulants | Plasma | Antiviral agents | Ritonavir | Lopinavir | Plasma levels | Hospitalization | Patients | Thrombosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Antiretroviral drug exposure in the female genital tract: Implications for oral pre- and post-exposure prophylaxis
by Dumond, Julie B and Yeh, Rosa F and Patterson, Kristine B and Corbett, Amanda H and Jung, Byung Hwa and Rezk, Naser L and Bridges, Arlene S and Stewart, Paul W and Cohen, Myron S and Kashuba, Angela D.M
AIDS (London), ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Virology | Antiviral agents | General aspects | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Epidemiology. Vaccinations | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy | Index Medicus | AIDS/HIV | genital tract | sexual transmission | antiretroviral therapy | pharmacokinetics | prophylaxis | women
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral Therapy. The ACTG (AIDS Clinical Trials Group) Study 5152s
by Torriani, Francesca J and Komarow, Lauren and Parker, Robert A and Cotter, Bruno R and Currier, Judith S and Dubé, Michael P and Fichtenbaum, Carl J and Gerschenson, Mariana and Mitchell, Carol K.C and Murphy, Robert L and Squires, Kathleen and Stein, James H and ACTG 5152s Study Team
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2008, Volume 52, Issue 7, pp. 569 - 576
endothelial function | human immunodeficiency virus | cardiovascular disease risk | antiretroviral therapy | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Antiviral agents | Immunopathology | Viral diseases | Biological and medical sciences | Medical sciences | Immunodeficiencies | Cardiology. Vascular system | Infectious diseases | Pharmacology. Drug treatments | Viral diseases of the lymphoid tissue and the blood. Aids | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Antibiotics. Antiinfectious agents. Antiparasitic agents | HIV-1 | Lamivudine - administration & dosage | Prospective Studies | Humans | Endothelium, Vascular - drug effects | Male | Stavudine - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Time Factors | Adult | Brachial Artery - physiopathology | Female | Brachial Artery - drug effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Ritonavir - administration & dosage | Lopinavir | CD4 Lymphocyte Count | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Endothelium, Vascular - pathology | HIV Infections - drug therapy | Pyrimidinones - administration & dosage | HIV Infections - physiopathology | Studies | Ultrasonic imaging | Human immunodeficiency virus--HIV | Deflation | Aging | Clinical trials | Infections | Diabetes | Drug therapy | Risk factors | Cholesterol | Veins & arteries | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009
by Abgrall, S and Ingle, S. M and May, M. T and Cornish, R and Costagliola, D and Mercie, P and Cavassini, M and Reekie, J and Samji, H and Gill, M. J and Crane, H. M and Tate, J and Sterling, T. R and Antinori, A and Reiss, P and Saag, M. S and Mugavero, M. J and Phillips, A and Manzardo, C and Wasmuth, J. C and Stephan, C and Guest, J. L and Sirvent, J. L. G and Sterne, J. A. C and Antiretroviral Therapy Cohort Coll and Antiretroviral Therapy Cohort Collaboration (ART-CC)
AIDS (London), ISSN 0269-9370, 2013, Volume 27, Issue 5, pp. 803 - 813
Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Virology | Antiviral agents | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | HIV-1 | United States - epidemiology | Lamivudine - administration & dosage | Humans | HIV Seropositivity - mortality | HIV Seropositivity - drug therapy | Nevirapine - adverse effects | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Adenine - adverse effects | Time Factors | Deoxycytidine - adverse effects | HIV Infections - mortality | Dideoxynucleosides - adverse effects | Antiretroviral Therapy, Highly Active - methods | Dideoxynucleosides - administration & dosage | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Risk Factors | Organophosphonates - adverse effects | Europe - epidemiology | Benzoxazines - adverse effects | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Lopinavir - administration & dosage | HIV Infections - drug therapy | Nevirapine - administration & dosage | Deoxycytidine - analogs & derivatives | Drug Combinations | Lopinavir - adverse effects | Cohort Studies | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study
by Boyd, Mark and SECOND-LINE Study Group and SECOND-LINE Study Grp
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 381, Issue 9883, pp. 2091 - 2099
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Nucleosides - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | HIV Infections - virology | Humans | Male | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | Nucleotides - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Lopinavir - administration & dosage | Adult | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Raltegravir Potassium | Complications and side effects | Reverse transcriptase inhibitors | Dosage and administration | Drug therapy | HIV infection | Low income groups | Studies | Antiretroviral drugs | Plasma | Hepatitis | Consent | Human immunodeficiency virus--HIV | Homeostasis | Drug resistance | Viral infections | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text COVID‐19 in solid organ transplant recipients: A single‐center case series from Spain
by Fernández‐Ruiz, Mario and Andrés, Amado and Loinaz, Carmelo and Delgado, Juan F and López‐Medrano, Francisco and San Juan, Rafael and González, Esther and Polanco, Natalia and Folgueira, María D and Lalueza, Antonio and Lumbreras, Carlos and Aguado, José M
American journal of transplantation, ISSN 1600-6135, 07/2020, Volume 20, Issue 7, pp. 1849 - 1858
treatment | coronavirus | solid organ transplantation | COVID‐19 | SARS‐CoV‐2 | outcome | Transplantation | Life Sciences & Biomedicine | Surgery | Science & Technology | Pandemics | Humans | Middle Aged | Male | Organ Transplantation | Coronavirus Infections - mortality | Transplant Recipients | COVID-19 | SARS-CoV-2 | Pneumonia, Viral - complications | Betacoronavirus | Coronavirus Infections - complications | Female | Retrospective Studies | Immunosuppressive Agents - administration & dosage | Interferon-beta - administration & dosage | Ritonavir - administration & dosage | Pneumonia, Viral - therapy | Antiviral Agents - administration & dosage | Fever | Hydroxychloroquine - administration & dosage | Spain - epidemiology | Coronavirus Infections - therapy | Lopinavir - administration & dosage | Immunosuppressive Agents - adverse effects | Aged | Pneumonia, Viral - mortality | Radiography, Thoracic | Drug Combinations | Severe acute respiratory syndrome coronavirus 2 | Hydroxychloroquine | Transplants & implants | Ritonavir | Lopinavir | Interferon | Coronaviruses | Health risk assessment | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
by Barlow, Ashley and Landolf, Kaitlin M and Barlow, Brooke and Yeung, Siu Yan Amy and Heavner, Jason J and Claassen, Cassidy W and Heavner, Mojdeh S
Pharmacotherapy, ISSN 0277-0008, 05/2020, Volume 40, Issue 5, pp. 416 - 437
dialysis | renal | antivirals | cytochrome P450 | infectious disease | liver | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Pandemics | Alanine - adverse effects | Adrenal Cortex Hormones | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Thiazoles - administration & dosage | Hydroxychloroquine - adverse effects | Thiazoles - adverse effects | Alanine - analogs & derivatives | Alanine - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Ritonavir - adverse effects | Ribavirin - administration & dosage | Betacoronavirus | Antibodies, Monoclonal, Humanized - adverse effects | Ritonavir - administration & dosage | Immunomodulation | Azetidines - adverse effects | Chloroquine - adverse effects | Antiviral Agents - administration & dosage | Adenosine Monophosphate - adverse effects | Hydroxychloroquine - administration & dosage | Nelfinavir - adverse effects | Interferon-alpha - administration & dosage | Azetidines - administration & dosage | Ribavirin - adverse effects | Adenosine Monophosphate - administration & dosage | Adenosine Monophosphate - analogs & derivatives | Antiviral Agents - adverse effects | Coronavirus Infections - therapy | Immunization, Passive | Lopinavir - administration & dosage | Sulfonamides - adverse effects | Chloroquine - administration & dosage | Interferon-alpha - adverse effects | Nelfinavir - administration & dosage | Drug Combinations | Lopinavir - adverse effects | Sulfonamides - administration & dosage | Severe acute respiratory syndrome coronavirus 2 | COVID-19 | Antiviral agents | Therapeutic applications | Clinical trials | Coronaviruses | Drug therapy | Patients | Index Medicus | Reviews of Therapeutics | Review of Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
by Eron, Joseph and Yeni, Patrick and Gathe, Joseph and Estrada, Vicente and DeJesus, Edwin and Staszewski, Schlomo and Lackey, Philip and Katlama, Christine and Young, Benjamin and Yau, Linda and Sutherland-Phillips, Denise and Wannamaker, Paul and Vavro, Cindy and Patel, Lisa and Yeo, Jane and Shaefer, Mark and for the KLEAN study team and KLEAN study team
The Lancet (British edition), ISSN 0140-6736, 2006, Volume 368, Issue 9534, pp. 476 - 482
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Immunopathology | General aspects | Infectious diseases | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Dideoxynucleosides - administration & dosage | Organophosphates - administration & dosage | Lamivudine - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | Humans | Lopinavir | Pyrimidinones - therapeutic use | Organophosphates - therapeutic use | Carbamates - administration & dosage | HIV Protease Inhibitors - administration & dosage | HIV-1 - genetics | Reverse Transcriptase Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Sulfonamides - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | HIV Infections - drug therapy | Dideoxynucleosides - therapeutic use | Pyrimidinones - administration & dosage | Reverse Transcriptase Inhibitors - therapeutic use | Carbamates - therapeutic use | Drug Therapy, Combination | Sulfonamides - administration & dosage | Dosage and administration | Protease inhibitors | Comparative analysis | Drug therapy | HIV infection | Antiviral agents | Research | Drug therapy, Combination | Health aspects | Anti-HIV agents | Antiretroviral drugs | Human immunodeficiency virus--HIV | Samples | Clinical trials | Comparative studies | Clinical medicine | Disease control | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Early Antiretroviral Therapy and Mortality among HIV-Infected Infants
by Violari, Avy and Cotton, Mark F and Gibb, Diana M and Babiker, Abdel G and Steyn, Jan and Madhi, Shabir A and Jean-Philippe, Patrick and McIntyre, James A and CHER Study Team
The New England journal of medicine, ISSN 0028-4793, 11/2008, Volume 359, Issue 21, pp. 2233 - 2244
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Infectious diseases | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | HIV-1 | Lamivudine - administration & dosage | Follow-Up Studies | Humans | Infant | Male | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Ritonavir - adverse effects | Treatment Failure | Female | HIV Infections - mortality | Drug Therapy, Combination | Drug Administration Schedule | Ritonavir - administration & dosage | Zidovudine - adverse effects | Anti-HIV Agents - adverse effects | Lopinavir | Pyrimidinones - adverse effects | CD4 Lymphocyte Count | Infectious Disease Transmission, Vertical | Disease Progression | HIV Infections - drug therapy | Pyrimidinones - administration & dosage | Antiviral agents | Control | Patient outcomes | Dosage and administration | HIV infection in children | Infants | Diagnosis | Antiretroviral drugs | Hospitals | Acquired immune deficiency syndrome--AIDS |